[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Xeris Biopharma Holdings (XERS) filed a Form 4 showing option exercises and a share sale by its Chief Executive Officer and Director. On 11/13/2025, the reporting person exercised stock options to acquire 8,970 shares of common stock at an exercise price of $1.55 per share and sold 23,242 shares of common stock at a weighted average price of $7.4607, all under a pre-arranged Rule 10b5-1 trading plan. After these transactions on that date, the reporting person held 2,643,153 shares of common stock directly. On 11/14/2025, the reporting person exercised additional stock options for 87,100 shares at $1.55 per share, increasing the directly held common stock position to 2,730,253 shares. Following these transactions, the person also held 64,265 stock options with an exercise price of $1.55 per share expiring on 02/03/2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shannon John Patrick Jr

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		M(1)		8,970	A	$1.55	2,666,395	D
Common Stock	11/13/2025		S(1)		23,242	D	$7.4607(2)	2,643,153	D
Common Stock	11/14/2025		M		87,100	A	$1.55	2,730,253	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.55	11/13/2025		M(1)			8,970	(3)	02/03/2027	Common Stock	8,970	$0	151,365	D
Stock Option (Right to Buy)	$1.55	11/14/2025		M			87,100	(3)	02/03/2027	Common Stock	87,100	$0	64,265	D

Explanation of Responses:

1. The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.

Remarks:

Chief Executive Officer and Director

	/s/ Beth Hecht, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Xeris Biopharma (XERS) report on this Form 4?

The filing reports that the Chief Executive Officer and Director of Xeris Biopharma Holdings, Inc. (XERS) exercised stock options and sold shares of common stock on 11/13/2025 and 11/14/2025. The transactions involve both the acquisition of shares through option exercises and the sale of a portion of the common stock.

How many XERS shares did the insider sell and at what price?

On 11/13/2025, the reporting person sold 23,242 shares of Xeris Biopharma common stock at a weighted average price of $7.4607 per share. The filing notes that the shares were sold in multiple trades at prices ranging from $7.260 to $7.740 per share.

How many Xeris Biopharma (XERS) stock options did the insider exercise and at what price?

The reporting person exercised stock options with an exercise price of $1.55 per share. On 11/13/2025, 8,970 options were exercised, and on 11/14/2025, an additional 87,100 options were exercised, each converting into an equal number of Xeris Biopharma common shares.

How many XERS shares does the insider own after these transactions?

Following the reported transactions, the filing shows that the reporting person directly owns 2,730,253 shares of Xeris Biopharma common stock. This figure reflects the exercises of stock options and the sale of shares described in the Form 4.

How many Xeris Biopharma stock options remain after the exercises?

After the option exercises reported on 11/13/2025 and 11/14/2025, the reporting person holds 64,265 stock options with an exercise price of $1.55 per share, expiring on 02/03/2027. These options relate to awards initially granted under the company's 2011 Stock Option/Stock Issuance Plan.

Were the XERS insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing explains that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Such plans are pre-arranged instructions for buying or selling securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What is the role of the reporting person at Xeris Biopharma (XERS)?

The reporting person is identified as the Chief Executive Officer and Director of Xeris Biopharma Holdings, Inc., indicating both an executive management and board-level role at the company.